Real-world single-centre experience of bimekizumab in patients with psoriasis: a 16-week retrospective observational study
{{output}}
Background: Bimekizumab inhibits interleukin-17A and interleukin-17F. Clinical trials have shown its efficacy in moderate--to-severe plaque psoriasis; however, real-world effectiveness and safety data remain limited. ... ...
